Why are benzodiazepines used less for routine ICU sedation now?

Benzodiazepine-based sedation is associated with more delirium and longer mechanical ventilation than propofol or dexmedetomidine, so guidelines generally favour non-benzodiazepine agents for many ventilated adults.

What makes dexmedetomidine different from propofol and benzodiazepines?

It acts on alpha-2 adrenergic receptors rather than GABA, producing a lighter, more arousable sedation with little respiratory depression, though large trials have shown its outcome benefits are population-dependent.

Sedative Agents in Critical Care

Sedative agents are drugs used in the intensive care unit to reduce agitation, relieve distress and allow tolerance of life-supporting therapies such as mechanical ventilation. The main classes used in critical care are propofol, the benzodiazepines (such as midazolam) and the alpha-2 agonist dexmedetomidine, each with distinct pharmacological profiles and associations with delirium and recovery.

Definition

Sedative (hypnotic-sedative) agents are central-nervous-system depressants administered in the ICU to produce calm, reduce agitation and facilitate tolerance of intensive care interventions, titrated to a target sedation level.

Scope

This topic covers the principal sedative drug classes used in adult critical care, the concept of light versus deep sedation, and the comparative evidence that has shifted practice away from continuous benzodiazepine infusions. It is a reference overview of the agents and the trials that inform their use, not a guide to selecting or dosing sedatives for a patient.

Key concepts

Propofol
Benzodiazepines (e.g. midazolam, lorazepam)
Dexmedetomidine (alpha-2 adrenergic agonist)
Light versus deep sedation
Sedation targeted to a validated scale
Benzodiazepine exposure and delirium risk
Drug accumulation and context-sensitive offset

Mechanisms

Most ICU sedatives act on the central nervous system to depress arousal. Propofol and benzodiazepines enhance inhibitory GABA-A receptor signalling, producing dose-dependent sedation and hypnosis; benzodiazepines additionally have amnestic and anticonvulsant effects but tend to accumulate and are associated with more delirium. Dexmedetomidine acts on central alpha-2 adrenergic receptors to produce a more arousable, 'cooperative' sedation with less respiratory depression, which is one reason guidelines favour non-benzodiazepine agents in many settings. The clinical behaviour of each agent depends on its distribution, metabolism and context-sensitive offset, which determine how quickly sedation lifts after stopping the infusion.

Clinical relevance

Choice and depth of sedation influence ventilator duration, delirium and recovery, so the comparative properties of these agents are central knowledge in critical care. The PADIS guidelines summarise the comparative evidence and generally favour light sedation with non-benzodiazepine agents; this entry presents that evidence base for orientation and is not a prescription for any individual patient.

Epidemiology

Sedatives are administered to the majority of mechanically ventilated patients. Trials including SEDCOM (Riker et al., 2009) and SPICE III (Shehabi et al., 2019) compared dexmedetomidine-based with benzodiazepine- or usual-care sedation, and studies of minimal sedation (Strøm et al., 2010) informed the broad trend toward lighter sedation.

Evidence & guidelines

The 2018 PADIS guidelines (Devlin et al.) suggest, where feasible, light over deep sedation and non-benzodiazepine sedatives (propofol or dexmedetomidine) over benzodiazepines for many ventilated adults, citing reduced delirium and shorter ventilation. SEDCOM and SPICE III refined understanding of dexmedetomidine's role, and the no-sedation trial by Strøm et al. demonstrated feasibility of minimal sedation strategies.

History

Continuous deep sedation, often with benzodiazepines, was common practice into the 2000s. Accumulating evidence that benzodiazepine-based and deep sedation prolonged ventilation and increased delirium drove successive guideline revisions toward propofol- and dexmedetomidine-based light sedation, a shift consolidated in the 2013 and 2018 SCCM guidelines.

Debates

Does dexmedetomidine improve patient-centred outcomes over other sedatives?: Early trials suggested less delirium and shorter ventilation with dexmedetomidine, but later large trials such as SPICE III found no overall mortality benefit and some harms, leaving its role nuanced and population-dependent.

Key figures

John Devlin
Yahya Shehabi
Richard Riker
Thomas Strøm

Seminal works

devlin-2018
riker-2009
shehabi-2019

Frequently asked questions

Why are benzodiazepines used less for routine ICU sedation now?: Benzodiazepine-based sedation is associated with more delirium and longer mechanical ventilation than propofol or dexmedetomidine, so guidelines generally favour non-benzodiazepine agents for many ventilated adults.
What makes dexmedetomidine different from propofol and benzodiazepines?: It acts on alpha-2 adrenergic receptors rather than GABA, producing a lighter, more arousable sedation with little respiratory depression, though large trials have shown its outcome benefits are population-dependent.